Drug Trial Radar · NCT05541107
Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial 3
Last checked: Nov 20, 2026Latest source record: Sep 15, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
270
Planned (sponsor's estimate)
Start
Jan 2023
Primary completion
Oct 2024
Study completion Jan 2025
Sponsor
- Lead sponsor
- Matinas BioPharma Nanotechnologies, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- University of Minnesota
- First posted
- Sep 15, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This pivotal, confirmatory trial seeks to independently verify the results observed in the EnACT Phase II Stage 2 trial (MB-70007).
Conditions
- Cryptococcal Meningitis
Interventions
MAT2203Drug
oral lipid nanocrystal amphotericin B
Amphotericin BDrug
Intravenous Amphotericin B
Primary outcomes
What the sponsor says the trial is designed to measure.
- SurvivalTime frame: 2 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.